|
It was announced Feb. 28, 2013 that over 80 Stryker lawsuits brought on behalf of patients who experienced pain, swelling, inflammation and infection after receiving the Stryker Rejuvenate and/or ABG II hip implants had been filed in New Jersey Superior Court. As per an order issued in January by New Jersey Supreme Court, these claims will be heard by Judge Brian R. Martinotti in Hackensack Superior Court. In federal court, a Stryker lawsuit plaintiff recently filed a motion to consolidate claims in the U.S. District Court for the District of Minnesota. He said 10 of the 30 Stryker lawsuits filed in federal court are pending at this location, so the creation of a multidistrict litigation (MDL) would serve the convenience of all parties. It would also avoid conflicting rulings by judges as well as reduce the possibility of duplicative discoveries. The patient who filed this lawsuit after the Stryker Rejuvenate recall says he experienced complications after receiving the Stryker Rejuvenate modular-neck hip stem. The following side effects are suggested to result from the Stryker hip recall issued July 6, 2012: • loosening; • pain and/or swelling at the local joint site; • metallosis; • immobility; and • inflammation of the surrounding tissue. To repair these complications, a patient may need to undergo revision surgeries. It is estimated that between January 2012 and July 6, 2012, the U.S. Food and Drug Administration (FDA) received at least 45 adverse event reports from patients who received the Stryker Rejuvenate and/or ABG II hip implants and allegedly suffered side effects. These Stryker lawsuits, which allege the manufacturer, Stryker Orthopaedics, failed to warn about the risks associated with its products, may soon cost the company more than it previously anticipated. On Jan. 23, MNSBC.com reported that Stryker’s net income dropped 33 percent in the fourth quarter and incurred a $133 million charge related to the Stryker Rejuvenate hip recall. A Jan. 9 report from Reuters also estimated that Stryker hip recalll expenses related to medical testing and treatment expenses could cost between $190 million and $390 million for affected patients. Revision surgeries, lawsuits and insurance payments will likely add to the company’s bill as well, the Jan. 9 article stated. Despite these possible expenses, Stryker says it expects its price per share to equal $4.25 and $4.40 in 2013. The Stryker hip recall was issued in July 2012 after post-surveillance data indicated the potential for metal components of the device to fret and corrode, which may lead to a host of complications. Symptoms of metallosis, which occurs when metallic debris sheds into a patient’s blood stream, may affect the heart, nerves, thyroid and kidney. As a result, symptoms may manifest in chest pain, shortness of breath, numbness, fatigue, weight gain and a change in urination habits. Before the announcement that these devices would be pulled from the market, 20,000 Stryker Rejuvenate implants were sold throughout the U.S. About : Bernstein Liebhard was formed in 1993 as a boutique litigation practice to represent plaintiffs in high-stakes, complex class action and individual litigation. Since that time, the firm has exclusively represented plaintiffs in various types of complex litigations, including securities class actions, shareholder derivative litigation, consumer protection class actions, mass tort litigation, private antitrust litigation, and qui tam/whistleblower litigation. Since inception, we have recovered over $3 billion on behalf of our clients and the classes we represent. Click hear
Related Articles -
Stryker Rejuvenate recall, Stryker lawsuits, Stryker Rejuvenate hip recall, Stryker hip recall,
|
